WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406991

CAS#: 1429179-07-6

Description: IDH889 is a potent and selective inhibitors of IDH1. IDH899 shows IDH (R132H) IC50 = 20 nM; Cell 2-HG IC50 = 14 nM. IDH889 demonstrates significantly improved plasma exposure in mice vs IDH662 (AUC 3.6 μM·h, Cmax 1.7 μM at 10 mg/kg; AUC 55.5 μM·h, Cmax 14.2 μM at 100 mg/kg). IDH889 also has excellent permeability and no efflux in the Caco-2 and human MDR1-MDCK cell lines, supporting the hypothesis that potent inhibition of mutant IDH1 function by binding at the allosteric binding site is compatible with brain penetration.

Chemical Structure

CAS# 1429179-07-6

Theoretical Analysis

MedKoo Cat#: 406991
Name: IDH889
CAS#: 1429179-07-6
Chemical Formula: C23H25FN6O2
Exact Mass: 436.2023
Molecular Weight: 436.4914
Elemental Analysis: C, 63.29; H, 5.77; F, 4.35; N, 19.25; O, 7.33

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: IDH889; IDH-889; IDH 889.

IUPAC/Chemical Name: (S)-3-(2-(((S)-1-(5-(4-fluoro-3-methylphenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one


InChi Code: InChI=1S/C23H25FN6O2/c1-13(2)19-12-32-23(31)30(19)20-7-8-25-22(29-20)28-15(4)21-26-10-17(11-27-21)16-5-6-18(24)14(3)9-16/h5-11,13,15,19H,12H2,1-4H3,(H,25,28,29)/t15-,19+/m0/s1

SMILES Code: CC1=C(F)C=CC(C2=CN=C([C@@H](NC3=NC(N4[C@@H](C(C)C)COC4=O)=CC=N3)C)N=C2)=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 436.4914 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1
Julian R. LevellThomas CaferroGregg ChenailIna DixJulia DooleyBrant FirestonePascal D. FortinJohn GiraldesTy GouldJoseph D. GrowneyMichael D. JonesRaviraj KulathilaFallon LinGang LiuArne MuellerSimon van der PlasKelly SlocumTroy SmithRemi TerranovaB. Barry TouréViraj TyagiTrixie WagnerXiaoling XieMing XuFan S. YangLiping X. ZhouRaymond PagliariniYoung Shin Cho
Publication Date (Web): December 16, 2016 (Letter)
DOI: 10.1021/acsmedchemlett.6b00334

Additional Information

Hotspot heterozygous mutations in human cytoplasmic isocitrate dehydrogenase 1 (IDH1) at Arg132 (R132*) have been identified in multiple cancer types, including acute myeloid leukemia (AML), glioma, chondrosarcoma, and cholangiocarcinoma.